ACADIA PHARMACEUTICALS INC. Debt Securities, Available-for-sale, Amortized Cost
ACADIA PHARMACEUTICALS INC. (ACAD) had Debt Securities, Available-for-sale, Amortized Cost of $572.95 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $572.95M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $569.46M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $640.50M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $587.97M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $572.95M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $569.46M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $640.50M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $587.97M 10-Q · filed 2025-11-06 |
| 2024-12-31 | $436.04M 10-K · filed 2026-02-26 |
| 2018-03-31 | $182.44M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $272.33M 10-Q · filed 2018-05-04 |
| 2017-09-30 | $254.09M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $273.64M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $312.02M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $365.32M 10-K · filed 2018-02-27 |
| 2016-09-30 | $434.66M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $280.59M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $281.72M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $113.00M 10-K · filed 2017-02-28 |
| 2015-09-30 | $169.86M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $177.56M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $221.47M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $260.65M 10-K · filed 2016-02-29 |
| 2014-09-30 | $301.36M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $340.67M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $275.60M 10-Q · filed 2014-05-06 |
| 2013-12-31 | $174.04M 10-K · filed 2015-02-26 |
| 2013-09-30 | $184.30M 10-Q · filed 2013-11-06 |
| 2013-06-30 | $197.97M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $87.77M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $56.38M 10-K · filed 2014-02-27 |
| 2012-09-30 | $16.29M 10-Q · filed 2012-11-05 |
| 2011-12-31 | $24.16M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |